Table 1.
PLGA-NPs | Particle size (nm) ± SD | Polydispersity ± SD | Zeta-potential (mV) ± SD | % Encapsulation ± SD | % Drug loading ± SD |
---|---|---|---|---|---|
With polyvinylpyrrolidone (PVP, w/v) | |||||
0.5%, (F1) | 785.35 ± 35.91 | 0.484 ± 0.008 | −14.51 ± 7.01 | 58.42 ± 3.58 | 5.92 ± 1.06 |
1.0%, (F2) | 174.46 ± 15.25 | 0.297 ± 0.015 | −15.82 ± 3.69 | 60.25 ± 4.92 | 6.75 ± 1.32 |
1.5%, (F3) | 295.51 ± 17.38 | 0.222 ± 0.012 | −6.04 ± 3.77 | 63.34 ± 3.85 | 7.26 ± 1.41 |
With D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS, w/v) | |||||
0.1%, (F4) | 293.61 ± 13.78 | 0.257 ± 0.013 | 15.28 ± 2.05 | 32.72 ± 2.98 | 7.67 ± 1.23 |
0.3%, (F5) | 262.38 ± 11.85 | 0.255 ± 0.011 | 15.14 ± 2.81 | 74.12 ± 6.19 | 8.65 ± 1.09 |
0.6%, (F6) | 716.15 ± 39.23 | 0.416 ± 0.023 | 11.67 ± 1.62 | 80.15 ± 7.85 | 5.15 ± 1.38 |
The values in bold indicate the selected formulation and its parameters.